Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey
Authors:
- Ruben MesaRMRuben Mesa
- Carole B. MillerCMCarole B. Miller
- Maureen ThyneMTMaureen Thyne
- James ManganJMJames Mangan
- Sara GoldbergerSGSara Goldberger
- Salman FazalSFSalman Fazal
- Xiaomei MaXMXiaomei Ma
- Wendy WilsonWWWendy Wilson
- Dilan C. ParanagamaDPDilan C. Paranagama
- David G. DubinskiDDDavid G. Dubinski
- John BoyleJBJohn Boyle
- John O. MascarenhasJMJohn O. Mascarenhas
Open Access
- 27 February 2016
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-10
Abstract
The Philadelphia chromosome−negative myeloproliferative neoplasms (MPN) myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) negatively affect patient quality of life (QoL) and are associated with increased risk of mortality. The MPN Landmark survey was conducted from May to July 2014 in patients with MF, PV, or ET under active management in the United States. The survey assessed respondent perceptions of disease burden and treatment management and included questions on overall disease burden, QoL, activities of daily living, and work productivity. Outcomes were further analyzed by calculated (ie, not respondent-reported) prognostic risk score and symptom severity quartile. The survey was completed by 813 respondents (MF, n = 207; PV, n = 380; ET, n = 226). The median respondent age in each of the 3 MPN subtypes ranged from 62 to 66 years; median disease duration was 4 to 7 years. Many respondents reported that they had experienced MPN-related symptoms ≥1 year before diagnosis (MF, 49 %; PV, 61 %; ET, 58 %). Respondents also reported that MPN-related symptoms reduced their QoL, including respondents with low prognostic risk scores (MF, 67 %; PV, 62 %; ET, 57 %) and low symptom severity (MF, 51 %; PV, 33 %; ET, 15 %). Many respondents, including those with a low prognostic risk score, reported that their MPN had caused them to cancel planned activities or call in sick to work at least once in the preceding 30 days (cancel planned activities: MF, 56 %; PV, 35 %; ET, 35 %; call in sick: MF, 40 %; PV, 21 %; ET, 23 %). These findings of the MPN Landmark survey support previous research about the symptom burden experienced by patients with MPNs and are the first to detail the challenges that patients with MPNs experience related to reductions in activities of daily living and work productivity.Keywords
This publication has 22 references indexed in Scilit:
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosisBlood, 2014
- Leukemic transformation in myeloproliferative neoplasms: Therapy-related or unrelated?Best Practice & Research Clinical Haematology, 2014
- The puzzle of myeloproliferative neoplasms: novel disease-specific mutations and new proposals for diagnostic criteriaBlood Research, 2014
- Epidemiology of myeloproliferative neoplasms in the United StatesLeukemia & Lymphoma, 2013
- Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based StudyJournal of Clinical Oncology, 2012
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patientsBlood, 2011
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling StudyJournal of Clinical Oncology, 2011
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)Blood, 2010
- The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)Cancer, 2006
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993